cdocker module within the biovia discovery studio 4.0 software (Accelrys)
90
Structured Review
Accelrys
cdocker module within the biovia discovery studio 4.0 software
Cdocker Module Within The Biovia Discovery Studio 4.0 Software, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdocker+module+within+the+biovia+discovery+studio+4%2E0+software/cdocker+module+of+discovery+studio+3+1/pm39725134-62-7-11
Average 90 stars, based on 1 article reviews
Cdocker Module Within The Biovia Discovery Studio 4.0 Software, supplied by Accelrys, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cdocker+module+within+the+biovia+discovery+studio+4%2E0+software/cdocker+module+of+discovery+studio+3+1/pm39725134-62-7-11
Average 90 stars, based on 1 article reviews
cdocker module within the biovia discovery studio 4.0 software - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Software:Article Title: Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2. Article Snippet: Multidrug resistance (MDR) remains a significant obstacle in cancer treatment, primarily attributable to the overexpression of ATP-binding cassette (ABC) transporters such as ABCB1 and ABCG2 within cancer cells.. These transporters actively diminish the effectiveness of cytotoxic drugs by facilitating ATP hydrolysis-dependent drug efflux, thereby reducing intracellular drug accumulation.. Given the absence of approved treatments for multidrug-resistant cancers and the established benefits of combining tyrosine kinase inhibitors (TKIs) with conventional anticancer drugs, we investigate the potential of vodobatinib, a potent c-Abl TKI presently in clinical trials, to restore sensitivity to chemotherapeutic agents in multidrug-resistant cancer cells overexpressing ABCB1 and ABCG2. |